Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells.

PubWeight™: 1.42‹?› | Rank: Top 5%

🔗 View Article (PMID 26012550)

Published in Mol Cell Biol on May 26, 2015

Authors

Antonella Sassano1, Evangelos Mavrommatis2, Ahmet Dirim Arslan2, Barbara Kroczynska3, Elspeth M Beauchamp1, Satya Khuon2, Ten-Leong Chew2, Kathleen J Green4, Hidayatullah G Munshi1, Amit K Verma5, Leonidas C Platanias6

Author Affiliations

1: Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA.
2: Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
3: Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
4: Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
5: Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
6: Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA l-platanias@northwestern.edu.

Articles cited by this

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27

How cells respond to interferons. Annu Rev Biochem (1998) 24.27

Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60

Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 11.57

Renal-cell carcinoma. N Engl J Med (2005) 10.17

Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33

Epidemiology and risk factors for kidney cancer. Nat Rev Urol (2010) 5.25

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43

Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum (2000) 3.23

Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature (2012) 2.98

Schlafen, a new family of growth regulatory genes that affect thymocyte development. Immunity (1998) 2.04

Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. J Cell Biol (2009) 1.99

The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc (2007) 1.82

Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif. Int Immunol (2004) 1.76

Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem (2002) 1.72

Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem (2001) 1.71

Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci (2000) 1.50

Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology (2013) 1.49

Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem (2004) 1.49

NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol Cell (2012) 1.44

The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes. Oncogene (2010) 1.43

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A (2012) 1.35

CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res (2011) 1.33

Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase. J Biol Chem (1995) 1.31

Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence. Gene (2009) 1.24

Notch signaling in chondrocytes modulates endochondral ossification and osteoarthritis development. Proc Natl Acad Sci U S A (2013) 1.16

Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. J Biol Chem (1995) 1.15

Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses. J Biol Chem (2009) 1.14

Subcellular localization of the Schlafen protein family. Biochem Biophys Res Commun (2008) 1.13

Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. J Biol Chem (2010) 1.12

The notch and TGF-β signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLoS One (2011) 1.11

Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res (2014) 1.09

Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Nucleic Acids Res (2013) 1.00

Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. Mol Cancer Res (2014) 0.99

The paternal gene of the DDK syndrome maps to the Schlafen gene cluster on mouse chromosome 11. Genetics (2005) 0.99

The schlafen family of proteins and their regulation by interferons. J Interferon Cytokine Res (2013) 0.99

Involvement of the Notch pathway in the regulation of matrix metalloproteinase 13 and the dedifferentiation of articular chondrocytes in murine cartilage. Arthritis Rheum (2009) 0.97

Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol (2003) 0.97

Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. Am J Physiol Gastrointest Liver Physiol (2011) 0.95

HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biol (2010) 0.89

Modulation of human renal cell carcinoma 786-0 MMP-2 and MMP-9 activity by inhibitors and inducers in vitro. Med Oncol (2006) 0.87

Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan. Anticancer Drugs (2014) 0.86

Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis. Oncotarget (2014) 0.84

Expression and regulatory effects of murine Schlafen (Slfn) genes in malignant melanoma and renal cell carcinoma. J Biol Chem (2013) 0.83

Schlafen 12 expression modulates prostate cancer cell differentiation. J Surg Res (2014) 0.79